Plus Therapeutics Q3 net loss widens

Cerenome

30/10/2025 20:33

Overview

Plus Therapeutics Q3 net loss widens to $4.4 mln from $2.9 mln last year

Company received $1.9 mln advance from CPRIT for radiotherapeutic development

Announced national coverage agreement with UnitedHealthcare for CNSide diagnostics

Outlook

Plus Therapeutics plans to expand commercial team and footprint for CNSide in Q4

Company aims to clarify REYOBIQ clinical development plan with FDA

Plus Therapeutics to bolster financial position in capital markets

Result Drivers

CNSIDE EXPANSION - Plus Therapeutics expanded commercial readiness for CNSide diagnostics, securing national coverage with UnitedHealthcare

CPRIT GRANT - Received $1.9 mln advance payment from CPRIT for leptomeningeal cancer targeted radiotherapeutic development

REYOBIQ TRIAL RESULTS - Presented positive ReSPECT-LM Phase 1 trial results showing promising efficacy for leptomeningeal metastases

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Net Income
-$4.42 mln
Q3 Operating Expenses
$5.87 mln
Q3 Operating Income
-$4.48 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Plus Therapeutics Inc is $4.00, about 86.5% above its October 29 closing price of $0.54

Press Release: ID:nGNX3Z8V6c

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)